Intas Pharmaceuticals Limited — Temozolomide Exporter Profile
Indian Pharmaceutical Exporter · #5 for Temozolomide · $825.2K export value · DGFT Verified
Intas Pharmaceuticals Limited is the #5 Indian exporter of Temozolomide with $825.2K in export value and 49 verified shipments. Intas Pharmaceuticals Limited holds a 3.5% market share in Temozolomide exports across 9 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Temozolomide Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Temozolomide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| POLAND | $178.7K | 7 | 18.9% |
| NETHERLANDS | $175.8K | 8 | 18.6% |
| UNITED STATES | $145.2K | 23 | 15.3% |
| FRANCE | $141.2K | 3 | 14.9% |
| THAILAND | $131.0K | 3 | 13.8% |
| ITALY | $60.6K | 3 | 6.4% |
| SPAIN | $53.2K | 5 | 5.6% |
| SOUTH AFRICA | $46.9K | 2 | 5.0% |
| AUSTRIA | $11.8K | 2 | 1.2% |
| MALTA | $2.0K | 3 | 0.2% |
Intas Pharmaceuticals Limited exports Temozolomide to 10 countries. The largest destination is POLAND accounting for 18.9% of Intas Pharmaceuticals Limited's Temozolomide shipments, followed by NETHERLANDS (18.6%) and UNITED STATES (15.3%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Temozolomide from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ALLIANCE PHARMA CO., LTD. | THAILAND | $131.0K | 3 |
| EVERSANA LIFE SCIENCES SERVICES,LLC | UNITED STATES | $130.9K | 22 |
| ACCORD HEALTHCARE B V | NETHERLANDS | $118.4K | 5 |
| XXCORXXHEAXXHCAXX POXXKA XX ZXX O | POLAND | $115.9K | 3 |
| XXCORXXHEAXXHCAXX B XX | FRANCE | $114.2K | 6 |
| XXCORXXHEAXXHCAXX SXX | ITALY | $97.8K | 5 |
| XXCORXXNL XX XXB | FRANCE | $96.3K | 2 |
| ACCORD HEALTHCARE POLSKA SP Z O O | POLAND | $62.8K | 4 |
| ACCORD HEALTHCARE PTY LTD | SOUTH AFRICA | $46.9K | 2 |
| ACCORD HEALTHCARE SLU | SPAIN | $16.1K | 3 |
Intas Pharmaceuticals Limited supplies Temozolomide to 14 buyers globally. The largest buyer is ALLIANCE PHARMA CO., LTD. (THAILAND), followed by EVERSANA LIFE SCIENCES SERVICES,LLC (UNITED STATES) and ACCORD HEALTHCARE B V (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Temozolomide Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $21.7M worth of Temozolomide through 1,261 shipments from 133 suppliers to 90 countries, serving 250 buyers globally. Intas Pharmaceuticals Limited contributes $825.2K to this total, accounting for 3.5% of India's Temozolomide exports. Intas Pharmaceuticals Limited ships Temozolomide to 10 countries through 14 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Temozolomide Exports?
Intas Pharmaceuticals Limited's average Temozolomide shipment value is $16.8K per consignment, based on 49 shipments totaling $825.2K. The largest destination is POLAND (18.9% of Intas Pharmaceuticals Limited's Temozolomide exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Temozolomide Exporters?
Intas Pharmaceuticals Limited ranks #5 among 133 Indian Temozolomide exporters with a 3.5% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($14.7M), JODAS EXPOIM PRIVATE LIMITED ($1.8M), RELIANCE LIFE SCIENCES PRIVATE LIMITED ($1.7M). Intas Pharmaceuticals Limited processed 49 shipments to 9 destination countries.
What Temozolomide Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TEMOZOLOMIDE ACCORD 140MG | $142.3K | 4 |
| TEMOZOLOMIDE ACCORD 20 | $93.2K | 8 |
| TEMOZOLOMIDE ACCORD 140 MG | $83.5K | 2 |
| TEMOZOLOMIDE ACCORD 140 | $50.0K | 1 |
| PH.DRU.& MED.: ZOLOTEM 250MG CAPSULES (EACH HARD GELATIN CAPSULES CONTAINS: TEMOZOLOMIDE 250MG) [1X5C PER PACK] | $50.0K | 1 |
| PH.DRU.& MED.: ZOLOTEM 100MG CAPSULES (EACH HARD GELATIN CAPSULES CONTAINS: TEMOZOLOMIDE 100MG) [1X5C PER PACK] | $50.0K | 1 |
| PHA.DRU & MEDI, TEMOZOL USP -100MG-5C-AMBER(US-ACCO EACH HARD GELATIN CAPSULE CONTAINS TEMOZOLOMIDE 100 MG 11912X1X5CNOS | $49.0K | 3 |
| TEMOZOLOMIDE ACCORD 180MG | $46.3K | 1 |
| TEMOZOLOMIDEACCORD 5MG | $45.0K | 1 |
| TEMOZOLOMIDE ACCORD 100MG | $41.5K | 1 |
Intas Pharmaceuticals Limited exports 25 distinct Temozolomide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TEMOZOLOMIDE ACCORD 140MG with 4 shipments worth $142.3K.
Regulatory Requirements: Exporting Temozolomide to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Temozolomide to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Temozolomide Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | RELIANCE LIFE SCIENCES PRIVATE LIMITED | $1.7M | 100 | 14 | $16.7K |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LTD | $950.0K | 19 | 4 | $50.0K |
| 5 | INTAS PHARMACEUTICALS LIMITED ★ | $825.2K | 49 | 9 | $16.8K |
| 6 | ACCURE LABS PRIVATE LIMITED | $631.0K | 45 | 1 | $14.0K |
| 7 | INTAS PHARMACEUTICALS LTD | $500.0K | 10 | 6 | $50.0K |
Intas Pharmaceuticals Limited ranks #5 among 133 Indian Temozolomide exporters. Average shipment value of $16.8K compared to the market average of $163.4K. The closest competitors by value are RELIANCE LIFE SCIENCES PRIVATE LIMITED and SUN PHARMACEUTICAL INDUSTRIES LTD.
Which Indian Ports Ship Temozolomide Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 247 | 19.6% |
| SAHAR AIR | 221 | 17.5% |
| NHAVA SHEVA SEA (INNSA1) | 112 | 8.9% |
| DELHI AIR CARGO ACC (INDEL4) | 99 | 7.9% |
| DELHI AIR | 72 | 5.7% |
| JNPT/ NHAVA SHEVA SEA | 53 | 4.2% |
| Bombay Air | 51 | 4.0% |
| HYDERABAD ACC (INHYD4) | 50 | 4.0% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Temozolomide Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Temozolomide, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Temozolomide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Temozolomide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 59 individual customs records matching Intas Pharmaceuticals Limited exporting Temozolomide, covering 25 formulations to 10 countries via 14 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 90+ countries, 250+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Temozolomide Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Temozolomide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Temozolomide Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Temozolomide. For current shipment-level data, contact TransData Nexus.